X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/01/29/2818900/0/en/First-Patient-Dosed-with-LIXTE-s-LB-100-and-GSK-s-Immunotherapy-Dostarlimab-gxly-in-Ovarian-Clear-Cell-Carcinoma-Trial.html
https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-zejula-combination-significantly-improved-progression-free-survival-in-endometrial-cancer-phase-iii-trial/
https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-chemotherapy-approved-as-the-first-and-only-frontline-immuno-oncology-treatment-in-the-european-union/
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-says-endometrial-cancer-drug-meets-primary-goal-late-stage-trial-2023-10-30/
https://www.fiercepharma.com/pharma/pd-1-battle-gsk-waged-merck-jermperli-appears-show-survival-edge-over-keytruda-lung-cancer
https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-new-data-in-non-small-cell-lung-cancer-and-endometrial-cancer-at-esmo/
https://www.fiercepharma.com/pharma/gsk-beats-merck-first-pd-1-approval-newly-diagnosed-endometrial-cancer
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174
https://endpts.com/italian-aav-biotech-closes-65m-series-a-gsks-jemperli-nabs-priority-review-in-endometrial-cancer/
https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-validates-marketing-authorisation-application-for-jemperli-dostarlimab/
https://endpts.com/gunning-for-2023-approval-gsk-details-phiii-data-for-jemperli-in-frontline-endometrial-cancer/
https://www.globenewswire.com/news-release/2023/03/27/2635287/0/en/AnaptysBio-and-GSK-partnered-immuno-oncology-agent-Jemperli-dostarlimab-gxly-plus-chemotherapy-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-progr.html
https://www.fiercepharma.com/pharma/new-pd-1-showdown-gsks-jemperli-lost-chance-winning-streak-over-mercks-keytruda
https://www.fiercepharma.com/pharma/gsks-unusual-jemperli-rectal-cancer-plan-wins-fda-advisers-backing-twist
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-dostarlimab-gxly-dmmr-endometrial-cancer#:~:tex[…]taining
https://www.prnewswire.com/news-releases/us-fda-grants-regular-approval-for-jemperli-for-the-treatment-of-patients-with-recurrent-or-advanced-mismatch-repair-deficient-endometrial-cancer-301743848.html
https://endpts.com/fda-assembles-adcomm-to-review-gsks-jemperli-trial-plans-in-rectal-cancer/
https://www.gsk.com/en-gb/media/press-releases/perla-phase-ii-trial-of-jemperli-dostarlimab-plus-chemotherapy-shows-positive-results-in-first-line-metastatic-non-squamous-non-small-cell-lung-cancer/
https://www.europeanpharmaceuticalreview.com/news/177243/dostarlimab-combination-facilitates-promising-lung-cancer-survival/
https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
https://www.fiercepharma.com/pharma/gsk-unveils-keytruda-head-head-data-lung-cancer-and-they-look-good-first-glance
https://www.fiercepharma.com/pharma/largest-head-head-trial-pd-1s-lung-cancer-gsk-thinks-jemperli-could-match-mercks-keytruda
https://endpts.com/asco22-rare-biomarker-leads-to-unprecedented-results-in-small-rectal-cancer-study/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174
https://eturbonews.com/3012708/endometrial-cancer-treatment-approved-in-canada/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761223
https://www.globenewswire.com/news-release/2021/08/17/2282311/0/en/FDA-Grants-Accelerated-Approval-of-JEMPERLI-dostarlimab-gxly-for-dMMR-Recurrent-or-Advanced-Solid-Tumors.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174
http://www.pharmatimes.com/news/evrysdi_leads_latest_chmp_recommendations_1364324
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-efficacy-data-of-dostarlimab-in-mismatch-repair-deficient-dmmr-solid-cancers-at-asco-gastrointestinal-cancers-symposium/
https://www.fiercebiotech.com/biotech/gsk-posts-middling-data-from-pd-1-tesaro-buyout-drug
https://www.fiercebiotech.com/biotech/barron-exhorts-gsk-scientists-to-take-smart-risks
https://www.reuters.com/article/us-gsk-dostarlimab/gsk-reports-positive-data-from-trial-of-endometrial-cancer-drug-idUSKCN1R02DG?feedType=RSS&feedName=healthNews
Market Place
Share 
